Albemarle Profit Rises to $296.8 Million
The Charlotte-based lithium and specialty chemicals maker posted third-quarter results that beat analyst estimates.
Updated on Nov. 4, 2026 in Corporate Finance
Albemarle Corp. reported third-quarter net income of $296.8 million, compared with a loss in the same period a year earlier. Profit was $2.15 per share, while adjusted earnings reached $2.58 per share.
Why it matters
The results came in above analyst expectations, with the company's revenue and adjusted earnings both exceeding Zacks Investment Research consensus estimates. The swing from a year-earlier loss to a profit marks a notable turnaround for the Charlotte-headquartered company.
Adjusted earnings of $2.58 per share beat the $2.56 analyst average, and revenue of $1.55 billion topped the $1.49 billion estimate, according to Zacks Investment Research's six-analyst survey. Albemarle shares, down 33% since January, closed near $94.97 on Wednesday, and the company's forward outlook was not addressed in the available data.
The players
Albemarle Corp.
Albemarle is a Charlotte, North Carolina-based specialty chemicals company and one of the world's largest lithium producers, serving battery and industrial markets.
Zacks Investment Research
Zacks Investment Research is an independent U.S. equity research firm known for its earnings estimate consensus data that analysts and investors use to gauge expectations.
The details
Albemarle reported the results on Wednesday, November 4, 2026. The company's net income stood at $296.8 million, a reversal from the loss it recorded in the same quarter of 2025.
Timeline
Q3 2025: Albemarle reported a loss in the same period.
November 4, 2026: Albemarle reported third-quarter earnings on Wednesday.
Market Dynamics
Albemarle's third-quarter results beat the Zacks Investment Research consensus on both earnings and revenue, even as the stock has fallen 33% since the start of the year. The divergence between operating results and share performance places the company's quarter against a broader market that has been pricing its shares lower through 2026.
Investors holding Albemarle shares are weighing a quarter that beat estimates against a stock down 33% this year, which may affect portfolio allocations in chemicals and lithium exposure. Retail holders should compare the reported per-share figures with their own cost basis before adjusting positions.
The takeaway
Albemarle's beat on both earnings and revenue shows the quarter was stronger than analysts expected, even though the shares have lagged this year. Readers tracking the stock should weigh the earnings surprise alongside the year-to-date decline.
Further reading
For more on how companies like this one are reporting results, see Corporate Finance coverage.
Source note: This article includes information reported by WTOP.
